Corcept Therapeutics, based in Menlo Park, California, is a commercial-stage pharmaceutical company that markets Korlym for Cushing's syndrome and has a portfolio of selective cortisol modulators. Founded in 2004, it employs 352 people and offers around 1,000 compounds.
William Guyer sold 7,060 shares of CORT on 6 May at $74.31 per share, worth a total of $525K. They now own 5,487 CORT shares, or a 56% holding decrease.
📡️ Health Care
Insider Trades
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
